HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report

HIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK–rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK–re...

Full description

Bibliographic Details
Main Authors: Aiko Ogimoto, MD, Naoko Katsurada, MD, PhD, Atsuhiko Yatani, MD, Chihiro Mimura, MD, Masatsugu Yamamoto, MD, PhD, Motoko Tachihara, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:JTO Clinical and Research Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001558